Literature DB >> 29267867

The benefit of pacemaker therapy in patients with neurally mediated syncope and documented asystole: a meta-analysis of implantable loop recorder studies.

Michele Brignole1, Jean Claude Deharo2, Carlo Menozzi3, Angel Moya4, Richard Sutton5, Marco Tomaino6, Andrea Ungar7.   

Abstract

Aim: Although the efficacy of cardiac pacing in patients with neurally mediated syncope (NMS) and documented asystole is established, a more robust point estimate of the benefit, which is not possible with any individual study, is lacking. Methods and results: We undertook a meta-analysis of individual participant data from four studies that reported follow-up data on syncope recurrence with cardiac pacing in patients with NMS who had had an electrocardiographic (ECG) documentation of an asystolic event by means of implantable loop recorder (ILR). Of a total of 1046 patients, who had ILR implanted, 383 (36.6%) patients had an ECG documentation of a diagnostic event during mean follow-up of 13 ± 10 months. Of these, 201 (52%) patients, corresponding to 19.2% of the total ILRs, had an asystolic event of 12.8 ± 11.0 s duration documented and met the criteria for pacemaker therapy. Follow-up was available in 121 (60%) of those patients with asystolic events. Syncope recurred after pacing in 18 (14.9%) patients with an actuarial rate of 13% [95% confidence interval (CI) ±6] at 1 year, 21% (95%CI ±10) at 2 years, and 24% (95%CI ±11) at 3 years. On multivariable Cox regression analysis, positive tilt test response was the only significant predictor of syncope recurrence with a hazard ratio (95% CI) of 4.3 (1.4-13). On the contrary, type of asystolic event (sinus arrest or atrioventricular block), prodrome, cardiac abnormalities, number and duration of history of syncope, age, and gender were not predictors of recurrence of syncope.
Conclusion: A long asystolic pause, suitable for pacemaker therapy, was found in one of five patients with ILR. After pacemaker implantation, most of these patients remained free of syncope recurrence for up to 3 years. The benefit of pacemaker was greater in patients with negative tilt test.

Entities:  

Mesh:

Year:  2018        PMID: 29267867     DOI: 10.1093/europace/eux321

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

Review 1.  Pathophysiology and Individualized Management of Vasovagal Syncope and Postural Tachycardia Syndrome in Children and Adolescents: An Update.

Authors:  Ying Liao; Junbao Du
Journal:  Neurosci Bull       Date:  2020-05-04       Impact factor: 5.203

Review 2.  Current approach to the treatment of vasovagal syncope in adults.

Authors:  Tarek Hatoum; Satish Raj; Robert Stanley Sheldon
Journal:  Intern Emerg Med       Date:  2022-09-18       Impact factor: 5.472

Review 3.  [Do we need syncope units? : Experience from Bolzano, South Tyrol (Italy)].

Authors:  Matthias Unterhuber; Marco Tomaino; Michele Brignole
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

Review 4.  [Management of syncope in clinical practice : What has changed according to the new ESC guidelines 2018?]

Authors:  S Oebel; G Hindricks
Journal:  Herz       Date:  2018-12       Impact factor: 1.443

Review 5.  Pacing in vasovagal syncope: Physiology, pacemaker sensors, and recent clinical trials-Precise patient selection and measurable benefit.

Authors:  Richard Sutton; Jelle S Y de Jong; Julian M Stewart; Artur Fedorowski; Frederik J de Lange
Journal:  Heart Rhythm       Date:  2020-02-06       Impact factor: 6.343

6.  Diagnosis and prevention of the vasodepressor type of neurally mediated syncope in Japanese patients.

Authors:  Misaki Hasegawa; Tomoyoshi Komiyama; Kengo Ayabe; Susumu Sakama; Tetsuri Sakai; Kyong Hee Lee; Masahiro Morise; Atsuhiko Yagishita; Mari Amino; Ayumi Sasaki; Eiichiro Nagata; Hiroyuki Kobayashi; Koichiro Yoshioka; Yuji Ikari
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.